| 000 | 01583 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517073848.0 | ||
| 264 | 0 | _c20161114 | |
| 008 | 201611s 0 0 eng d | ||
| 022 | _a1872-8332 | ||
| 024 | 7 |
_a10.1016/j.lungcan.2015.12.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCaumont, Charline | |
| 245 | 0 | 0 |
_aNeuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma. _h[electronic resource] |
| 260 |
_bLung cancer (Amsterdam, Netherlands) _cFeb 2016 |
||
| 300 |
_a15-8 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAdenocarcinoma of Lung |
| 650 | 0 | 4 | _aAnaplastic Lymphoma Kinase |
| 650 | 0 | 4 |
_aClavicle _xpathology |
| 650 | 0 | 4 | _aCrizotinib |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Rearrangement |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xpathology |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aPyridines _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xgenetics |
| 700 | 1 | _aVeillon, Rémi | |
| 700 | 1 | _aGros, Audrey | |
| 700 | 1 | _aLaharanne, Elodie | |
| 700 | 1 | _aBégueret, Hugues | |
| 700 | 1 | _aMerlio, Jean-Philippe | |
| 773 | 0 |
_tLung cancer (Amsterdam, Netherlands) _gvol. 92 _gp. 15-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.lungcan.2015.12.001 _zAvailable from publisher's website |
| 999 |
_c25638147 _d25638147 |
||